|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Baselga J et al. Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006;11(Suppl 1):4-12. Abstract
Carlson RW; NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):1-22. Abstract
Geyer CE Jr et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)
paclitaxel (T) vs ACT with trastuzumab (H). Proc ASCO 2006;Abstract 581.
Gonzalez-Angulo AM et al. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006;11(8):857-67. Abstract
Hurley J et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2- positive locally advanced breast cancer. J Clin Oncol 2006;24(12):1831-8. Abstract
Joensuu H et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Kelly H et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006;7(3):237- 43. Abstract
Love N; Research To Practice. Management of breast cancer in the adjuvant and metastatic settings. Patterns of Care in Medical Oncology 2005;2(1).
Love N; Research To Practice. Management of breast cancer in the adjuvant and metastatic settings. Patterns of Care in Medical Oncology 2005;2(2).
Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: Trastuzumab adjuvant and neoadjuvant trials. Expert Opin Biol Ther 2006;6(9):951-62. Abstract
Perez EA et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24(19):3032-8. Abstract
Persons DL et al. HER-2 fluorescence in situ hybridization: Results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 2006;130(3):325-31. Abstract
Piccart-Gebhart MJ. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: What we know and what we still need to learn. Eur J Cancer 2006;42(12):1715-9. Abstract
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659- 72. Abstract
Press MF et al. Diagnostic evaluation of HER- 2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11(18):6598- 607. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673- 84. Abstract
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast
Cancer Symposium 2005;Abstract 1.
Smith KL et al. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 2006;5(5):619-29. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
Tsuda H. HER-2 (c-erbB-2) test update: Present status and problems. Breast Cancer 2006;13(3):236-48. Abstract
 |
 |
Editor’s Note:
Let’s get this thing done.
Prologue:
The adjuvant trastuzumab clinical research to
practice model
- Select publications
Breast Cancer Clinical Trials:
Neoadjuvant Therapy
 |
 |
 |
 |
 |
